<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997815</url>
  </required_header>
  <id_info>
    <org_study_id>SirirajH</org_study_id>
    <nct_id>NCT00997815</nct_id>
  </id_info>
  <brief_title>The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis</brief_title>
  <official_title>The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Siriraj Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Siriraj Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the efficacy of intralesional botulinum toxin
      type A injection for recalcitrant alopecia totalis and alopecia universalis.

      Treatments of recalcitrant alopecia totalis and universalis remains an challenge issue for
      medical practice.The application of diphenylcyclopropenone (DPCP) is still being an standard
      treatment for the condition, however, there are at least thirty percentage of patients
      recalcitrant to this treatment.

      The complete etiology of this disease has yet to be clear.Nevertheless,recent studies have
      demonstrated the hypothesis of neurotransmitter involvements.

      There is numerous evidence in support of an imbalance of transmitters, including substance P
      and Calcitonin gene-related peptide.

      Botulinum toxin A injection has been used to treat a neuralgiform headache and diffused
      alopecia areata. Both headache and hair loss have been made much in improvement. This data
      may support the neurotransmitter imbalance theory.

      The investigators have been informed about possible effects to the alopecia condition,
      therefore, this study is conducted to assess the efficacy of botulinum toxin A as the novel
      treatment for recalcitrant alopecia totalis and alopecia universalis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the percentage of terminal hair regrowth in recalcitrant alopecia totalis and alopecia universalis after intralesional botulinum toxin A injection</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate any possible side effects of intralesional botulinum toxin A injection for alopecia totalis and alopecia universalis</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Recalcitrant Alopecia Totalis</condition>
  <condition>Recalcitrant Alopecia Universalis</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The area of alopecia is splited into experimental and control sides by blocked randomization. Experimental sides injected with botulinum toxin A at 2 units per 0.1 ml of dilution with normal saline entire all area.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Using normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin A</intervention_name>
    <description>Concentration at 2 units per 0.1 of normal saline dilution</description>
    <arm_group_label>Botulinum toxin A</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline injection</intervention_name>
    <description>Using normal saline 2.5 ml injected in control side</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients must be over 18 years old

          2. All patients are diagnosed with alopecia totalis or alopecia universalis

          3. The alopecia condition was not responded to any treatments

        Exclusion Criteria:

          1. Having an active inflammation on scalp area

          2. Allergic to botulinum toxin A of human albumin

          3. Has been diagnosed with neuromuscular disorders

          4. Taking any medication that may interfere with botulinum toxin A action

          5. Receiving any treatment for alopecia condition within 4 weeks

          6. Pregnant , breastfeeding, plan to pregnant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rattapon Thoungtong, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Dermatology, Faculty of medicine Siriraj Hospital, Mahidol University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Supenya Varothai, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rasthawathana Desomchoke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Suthasinee Pattaravadee, B.Sc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2009</study_first_submitted>
  <study_first_submitted_qc>October 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <last_update_submitted>August 1, 2012</last_update_submitted>
  <last_update_submitted_qc>August 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Siriraj Hospital</investigator_affiliation>
    <investigator_full_name>Rattapon Thuangtong</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>Recalcitrant</keyword>
  <keyword>Alopecia totalis</keyword>
  <keyword>Alopecia universalis</keyword>
  <keyword>Botulinum toxin A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

